Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2014 4
2015 3
2018 1
2019 2
2021 5
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, López-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Dagnew AF, et al. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6. Lancet Infect Dis. 2019. PMID: 31399377 Clinical Trial.
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A; ZOE-50/70 study group. Dagnew AF, et al. Rheumatology (Oxford). 2021 Mar 2;60(3):1226-1233. doi: 10.1093/rheumatology/keaa424. Rheumatology (Oxford). 2021. PMID: 32910152 Free PMC article.
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
Stadtmauer EA, Sullivan KM, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C, Anttila VJ, Bloor AJ, Broady R, Cellini C, Cuneo A, Dagnew AF, Di Paolo E, Eom H, González-Rodríguez AP, Grigg A, Guenther A, Heineman TC, Jarque I, Kwak JY, Lucchesi A, Oostvogels L, Polo Zarzuela M, Schuind AE, Shea TC, Sinisalo UM, Vural F, Yáñez San Segundo L, Zachée P, Bastidas A. Stadtmauer EA, et al. Among authors: dagnew af. Hum Vaccin Immunother. 2021 Nov 2;17(11):4144-4154. doi: 10.1080/21645515.2021.1953346. Epub 2021 Aug 18. Hum Vaccin Immunother. 2021. PMID: 34406911 Free PMC article. Clinical Trial.
End-point definition and trial design to advance tuberculosis vaccine development.
Garcia-Basteiro AL, White RG, Tait D, Schmidt AC, Rangaka MX, Quaife M, Nemes E, Mogg R, Hill PC, Harris RC, Hanekom WA, Frick M, Fiore-Gartland A, Evans T, Dagnew AF, Churchyard G, Cobelens F, Behr MA, Hatherill M. Garcia-Basteiro AL, et al. Among authors: dagnew af. Eur Respir Rev. 2022 Jun 7;31(164):220044. doi: 10.1183/16000617.0044-2022. Print 2022 Jun 30. Eur Respir Rev. 2022. PMID: 35675923 Free article. Review.
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Hervé C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL. Oostvogels L, et al. Among authors: dagnew af. Hum Vaccin Immunother. 2019;15(12):2865-2872. doi: 10.1080/21645515.2019.1627818. Epub 2019 Jun 28. Hum Vaccin Immunother. 2019. PMID: 31216205 Free PMC article. Clinical Trial.
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Hussein J, Zewdie M, Yamuah L, Bedru A, Abebe M, Dagnew AF, Chanyalew M, Yohannes AG, Ahmed J, Engers H, Doherty TM, Bang P, Kromann I, Hoff ST, Aseffa A. Hussein J, et al. Among authors: dagnew af. Trials. 2018 Jan 10;19(1):24. doi: 10.1186/s13063-017-2354-0. Trials. 2018. PMID: 29321075 Free PMC article. Clinical Trial.
17 results